#USA #New York #Faruqi & Faruqi #Josh Wilson #Capricor Therapeutics

Investor Claims Investigation: Capricor Therapeutics

Recently, the prominent securities law firm Faruqi & Faruqi, LLP has taken steps to investigate significant claims regarding Capricor Therapeutics, Inc. This investigation is especially pertinent for those investors who might have incurred losses exceeding $75,000 between October 9, 2024, and July 10, 2025. The firm has highlighted the approaching deadline of September 15, 2025, which marks the last day for potential lead plaintiffs to come forward in a federal securities class action filed against the company.

Background of the Investigation

Faruqi & Faruqi, based in New York with additional offices in Pennsylvania, California, and Georgia, has a solid track record, having secured hundreds of millions of dollars in recoveries for investors since its inception in 1995. The firm aims to ensure that investors are aware of their rights and opportunities, especially in light of the troubling developments surrounding Capricor Therapeutics.

The central issue of this investigation revolves around allegations that Capricor and its executives made misleading statements about their lead drug therapy candidate, deramiocel. This drug targets cardiomyopathy linked to Duchenne muscular dystrophy (DMD). Furthermore, investors claim that Capricor failed to disclose crucial information regarding the safety and efficacy data related to the drug, which is paramount to its approval by the U.S. Food and Drug Administration (FDA).

Allegations Against Capricor

The complaint against Capricor claims that the company misled investors about its ability to secure a Biologics License Application (BLA) from the FDA for deramiocel. Notably, the statements assured stakeholders of the drug's approval potential while omitting significant adverse facts about the trial's outcome. Particularly, the firm is accused of concealing critical safety data from the Phase 2 HOPE-2 trial, which played a vital role in the drug's evaluation process.

On July 11, 2025, investors received alarming news when Capricor released a press announcement stating it had received a Complete Response Letter (CRL) from the FDA. The letter detailed that Capricor had not met the necessary statutory requirements for demonstrating the drug's effectiveness, alongside the need for further clinical data and outstanding issues regarding the drug's manufacturing processes. This announcement led to a drastic drop in Capricor’s stock price, tumbling from $11.40 a share on July 10 to just $7.64 the following day.

Call to Action for Investors

James (Josh) Wilson, a Senior Partner at Faruqi & Faruqi, encourages affected investors to explore their legal options promptly. Investors who wish to discuss their potential claims or seek more information about the ongoing investigation are advised to contact Wilson directly at the firm's office.

Moreover, any individuals with pertinent information regarding Capricor's practices, including whistleblowers and former employees, are encouraged to reach out to the firm to assist in their investigation. The firm strives to gather all relevant information to support the case effectively.

Faruqi & Faruqi has established a website dedicated to providing updates about the lawsuit and the class action process. For those interested in learning more about Capricor Therapeutics and the steps to take if they believe they are affected, detailed information can be found at the law firm’s official page.

Conclusion

As the deadline of September 15 approaches, investors of Capricor Therapeutics should act swiftly and consider their options carefully. With the oversight of experienced attorneys at Faruqi & Faruqi, there is a clear pathway for those looking to assert their rights and seek reparations for their losses in the turbulent landscape of biotech investments. Investors are not only encouraged to remain informed but also to take part in the legal process which could shape the outcome of this significant case.